We report a case of endocarditis due to a penicillin-"resistant" Streptococcus parasanguinis, discuss interpretations of the American Heart Association's guidelines for the treatment of viridans group streptococcal infection, and comment on therapy for infective endocarditis due to penicillin-resistant viridans group streptococci.
The 2005 publication of the American Heart Association's scientific statement on management of infective endocarditis (AHA-IE) has helped summarize the evidence base and codify the treatment of patients with infective endocarditis (IE) [1] . We recently encountered a patient with IE due to penicillin G-"resistant" Streptococcus parasanguinis, which is a viridans group Streptococcus (VGS) species. This case presented several clinical issues for which available data are meager and/or confusing. We discuss treatment of IE due to penicillin-resistant VGS.
Case report. A 56-year-old man presented to the hospital with a history of weight loss, worsening dyspnea on exertion, orthopnea, and lower extremity edema. He noted recent purulent discharge from a heroin injection site on his right thigh and subjective fevers during the 4 days before hospital admission. Cardiac examination revealed a II/VI early diastolic murmur best heard at the apex. Two sets of blood samples were obtained for culture, and therapy with intravenously admin-istered vancomycin (750 mg every 12 h) and gentamicin (80 mg every 8 h, equivalent to 3 mg/kg per day) was commenced on the day of admission.
Transesophageal echocardiography revealed a 2.0-cm aortic valve vegetation, severe aortic insufficiency, mild mitral regurgitation, and normal ejection fraction. All 4 blood culture bottles yielded growth; 3 bottles yielded an organism identified as Streptococcus parasanguinis, as determined using the Vitek 2 system. The MIC of penicillin G for this isolate was 4.0 mg/ mL, as determined by Etest (AB Biodisk) (table 1). Two of the 4 blood culture bottles also yielded Streptococcus mitis, for which the MIC of penicillin G was 0.25 mg/mL, as determined by Etest. The results of blood cultures performed during treatment were negative.
On day 10 of hospitalization, vancomycin was switched to ceftriaxone (2 g intravenously per day); gentamicin treatment was discontinued on day 16 because of worsening renal function. On day 18, the patient underwent surgery because of the progressing severity of congestive heart failure. Intra-operative transesophageal echocardiography revealed severe mitral regurgitation, a small vegetation on the anterior mitral leaflet, and aortic insufficiency with a 1.9-cm aortic valve vegetation; both valves were replaced with porcine bioprostheses. After surgery, vancomycin was administered to complete treatment of IE and lumbosacral osteomyelitis, which had been diagnosed preoperatively. The patient received a total of 56 days of antimicrobial therapy (vancomycin-gentamicin for 10 days, ceftriaxone-gentamicin for 8 days, and vancomycin monotherapy for 38 days); gentamicin treatment was withheld because of postoperative renal dysfunction that normalized by the time of discharge from the hospital.
MICs and minimal bactericidal concentrations were determined, and a synergy test of selected antimicrobials for S. parasanguinis was performed (table 1). In vitro antimicrobial synergy was detected with the combination of penicillin G and gentamicin (table 1). When the patient was last seen (6 weeks after the completion of treatment), he was afebrile, felt well, and was considered to be cured. The patient died of unknown causes ∼4 months after discharge from the hospital.
Discussion. The AHA-IE [1] defines VGS as highly susceptible to penicillin G if the MIC is р0.12 mg/mL, relatively resistant if the MIC is 10.12 and р0.5 mg/mL, and resistant if the MIC is 10.5 mg/mL. These definitions differ from the Clinical Laboratory Standards Institute (CLSI; formerly the NCCLS) interpretative criteria for susceptibility of VGS to penicillin G. The CLSI considers VGS to be fully susceptible to penicillin G if the MIC is р0.12 mg/mL, to have intermediate susceptibility if the MIC is 0.25-2.0 mg/mL, and to be resistant if the MIC is у4.0 mg/mL [2] . However, the CLSI interpretive criteria are not applicable to IE due to VGS. We believe that the AHA-IE definitions of VGS resistance and the recommendations for therapy are based on the following: (1) the finding that addition of an aminoglycoside to a regimen of penicillin or ceftriaxone for treatment of infection with VGS that is highly susceptible to penicillin G allows for a shorter treatment course, (2) the recognition that bactericidal activity of a treatment regimen generally correlates with a greater likelihood of cure of IE, and (3) the recognition that the bactericidal activity of penicillin G cannot be predicted to be present for strains of VGS that have MICs of penicillin G 10.12 mg/mL. These considerations led to the recommendation that gentamicin be added to a regimen of penicillin G or ceftriaxone for strains with MICs 10.12 mg/mL. However, clinical studies to support a beneficial effect of aminoglycoside cotreatment have been lacking. It is not known whether penicillin G monotherapy is less likely to cure IE due to VGS when the MIC of penicillin G is appreciably greater than 0.12 mg/mL but still !4 mg/mL (as occurred in our patient), nor is it known whether the MIC of penicillin G is a proxy for the potential lack of efficacy of either ceftriaxone or vancomycin for the treatment of VGS IE.
Although synergy testing might provide useful information for treatment of patients with penicillin G-resistant VGS IE, data documenting a correlation between favorable clinical outcomes and synergy between b-lactams and aminoglycosides are anecdotal [3] . To our knowledge, kill-curve synergy testingthe preferred method [3] -is not readily available for clinical care. We were able to obtain "synergy" data using a modified checkerboard technique [4] , which indicated a substantial reduction in the MIC (but not the minimal bactericidal concentration) of penicillin G when our patient's isolate was grown in the presence of gentamicin (table 1) .
The AHA-IE criteria [1] for fully susceptible VGS (MIC of penicillin G, р0.12 mg/mL) are based on reasonable clinical data. Their recommendations for treatment of IE due to relatively resistant strains of VGS (MIC, у0.25 to р0.5 mg/mL) call for the addition of gentamicin for the first 2 weeks of treatment. Although the data are limited, this recommendation has merit. However, the recommendation for the treatment of penicillin G-resistant VGS that appears in table 5 of the AHA-IE document is confusing: "Patients with endocarditis caused by penicillin-resistant strains (MIC 10.5 mg/mL) should be treated with a regimen recommended for enterococcal endocarditis (table 9)"; a similar statement appears in the text on page e403. (Table 9 in the AHA-IE [1] contains recommendations for treatment of enterococcal IE and, quite appropriately, does not mention the use of ceftriaxone.) Similarly, the guidelines of the Working Party of the British Society for Antimicrobial Therapy for treatment of endocarditis [5] recommend that "treatment of more resistant viridans streptococci (penicillin MIC у0.5 mg/L) should follow the recommendations for treating enterococci" (p. 976). We believe that patients who are infected with highly resistant strains of VGS (MIC of penicillin G, 10.5 mg/mL) should be treated for at least 4 weeks with a combination of high-dose penicillin or ceftriaxone plus low-dose gentamicin (3 mg/kg/day in 3 divided doses, assuming normal renal function) whenever feasible; the dosage of gentamicin should be adjusted to achieve peak serum concentrations of 3-4 mg/mL and trough serum concentrations of !1 mg/mL. We also believe that vancomycin should be reserved for penicillin-ceftriaxone-intolerant patients and that routine addition of an aminoglycoside to vancomycin therapy, although appropriate for treatment of enterococcal IE [1, 5] , is unnecessary for treatment of VGS IE [1] . The occurrence of appreciable nephrotoxicity in a patient receiving a b-lactam-gentamicin combination would warrant a reassessment of the risk-benefit of gentamicin.
We acknowledge that, for isolates with MICs of penicillin G 10.12 mg/mL, there is debate regarding the benefit of adding gentamicin to a regimen of penicillin G or ceftriaxone [3, 5, 6] ; prospective, comparative clinical trials to address this question do not appear to be feasible. However, Knoll et al. [7] recently reported a retrospective study of 29 patients with IE due to either relatively resistant or resistant VGS; these 29 cases spanned a 39-year period at the Mayo Clinic (Rochester, MN). Nine of the infecting strains were relatively resistant to penicillin G (MIC, 0.5 mg/mL), and 20 strains were resistant, with MICs of 1.0-4.0 mg/mL. Sixteen of 19 patients with native valve endocarditis received a combination of a b-lactam agent and an aminoglycoside; 17 of 19 were cured. Ten of the patients had prosthetic valve endocarditis, and 9 of the 10 received a combination of a b-lactam agent plus an aminoglycoside (often streptomycin). All 10 with prosthetic valve endocarditis were cured; 1 had multiple relapses before cure. Although such data do not prove a greater efficacy of a b-lactam-aminoglycoside combination, they do indicate that such a combination is likely to be curative. Currently, gentamicin is preferable to streptomycin, given the greater ease of administration and ability to monitor drug levels. We believe that these data [7] support the recommendation that IE due to VGS that is relatively resistant or resistant to penicillin G should be treated with either penicillin G or ceftriaxone and gentamicin. This approach has recently been advocated by Le and Bayer [3] . For isolates with an MIC of penicillin G у4 mg/mL or an MIC of ceftriaxone у4 mg/mL [2] , vancomycin (if active) may be the most prudent choice for treatment.
In table 2, we summarize our recommendations for the treatment of native valve endocarditis due to VGS; these have been adapted from the AHA IE guidelines [1] . Physicians should be aware that VGS that is relatively resistant to penicillin G (MIC, 10.12 mg/mL) and VGS that is resistant to penicillin G (MIC, 10.5 mg/mL) occasionally cause IE and that the data on which the AHA-IE guidelines are based, unfortunately, are relatively meager. Although relatively simple techniques for synergy testing are not standardized, we believe that in vitro testing of penicillin-resistant VGS (MIC, 10.5 mg/mL) for penicillin Ggentamicin and ceftriaxone-gentamicin synergy may provide additional useful information. If synergy cannot be assessed via a time-kill assay, then assessment for in vitro synergy using a checkerboard technique is reasonable.
